Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (NCT06562192)

🧪 Interventions in This Study

• [68Ga]Ga-NNS309 (DRUG)
• [177Lu]Lu-NNS309 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

• Uni of Alabama at Birmingham — Birmingham, Alabama
• University of California LA — Los Angeles, California
• Stanford University Medical Center — Palo Alto, California
• Mayo Clinic Jacksonville — Jacksonville, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• BAMF Health — Grand Rapids, Michigan
• Mayo Clinic Rochester — Rochester, Minnesota
• Uni Of TX MD Anderson Cancer Cntr — Houston, Texas
• University Of Washington — Seattle, Washington
• Novartis Investigative Site — Brussels,
• Novartis Investigative Site — Toronto, Ontario
• Novartis Investigative Site — Montreal, Quebec
• Novartis Investigative Site — Montreal, Quebec
• Novartis Investigative Site — Bron,
• Novartis Investigative Site — Villejuif,
• Novartis Investigative Site — Cologne, North Rhine-Westphalia
• Novartis Investigative Site — Essen,
• Novartis Investigative Site — München,
• Novartis Investigative Site — Rostock,
• Novartis Investigative Site — Tel Aviv,
• Novartis Investigative Site — Milan, MI
• Novartis Investigative Site — Reggio Emilia, RE
• Novartis Investigative Site — Nijmegen, Gelderland
• Novartis Investigative Site — Utrecht,
• Novartis Investigative Site — Barcelona,

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pancreatic Ductal Adenocarcinoma

• A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Rochester, New York
• Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) — Kansas City, Kansas
• Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer — Durham, North Carolina
• Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer — Washington D.C., District of Columbia
• A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma — Philadelphia, Pennsylvania
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma — Los Angeles, California

Explore by condition: All Pancreatic Ductal Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.